XBIT
Closed
Xbiotech Inc
6.52
+0.26 (+4.15%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 6.26
Day's Range: 6.27 - 6.69
Send
sign up or login to leave a comment!
When Written:
3.65
XBiotech Inc is a biopharmaceutical company based in Austin, Texas, USA. The company focuses on the development and commercialization of monoclonal antibody therapies for the treatment of various diseases, including cancer, infectious diseases, and inflammatory conditions.
XBiotech's lead product candidate, bermekimab, is a human monoclonal antibody that targets interleukin-1 alpha (IL-1α), a pro-inflammatory cytokine. Bermekimab is currently in clinical trials for the treatment of various inflammatory conditions, including atopic dermatitis, hidradenitis suppurativa, and COVID-19.
XBiotech was founded in 2005 by John Simard, who currently serves as the company's CEO. The company has collaborations with various academic and research institutions, including the University of Texas MD Anderson Cancer Center and the University of California, Los Angeles.
As of 2021, XBiotech has a market capitalization of approximately $1.1 billion and is traded on the NASDAQ stock exchange under the ticker symbol XBIT.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
XBiotech's lead product candidate, bermekimab, is a human monoclonal antibody that targets interleukin-1 alpha (IL-1α), a pro-inflammatory cytokine. Bermekimab is currently in clinical trials for the treatment of various inflammatory conditions, including atopic dermatitis, hidradenitis suppurativa, and COVID-19.
XBiotech was founded in 2005 by John Simard, who currently serves as the company's CEO. The company has collaborations with various academic and research institutions, including the University of Texas MD Anderson Cancer Center and the University of California, Los Angeles.
As of 2021, XBiotech has a market capitalization of approximately $1.1 billion and is traded on the NASDAQ stock exchange under the ticker symbol XBIT.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
3.65
XBiotech Inc. is a biopharmaceutical company based in Austin, Texas. The company specializes in the discovery, development, and commercialization of therapeutic antibodies for the treatment of various diseases, including cancer, infectious diseases, and inflammatory disorders. XBiotech's lead product candidate, bermekimab, is a monoclonal antibody that targets interleukin-1 alpha (IL-1α), which is believed to play a role in a variety of inflammatory diseases. The company has also developed a platform technology for the production of human antibodies, which it believes will enable it to rapidly develop new therapeutics for a wide range of diseases. XBiotech was founded in 2005 by John Simard, who currently serves as the company's CEO. The company went public in 2015 and is traded on the NASDAQ under the ticker symbol XBIT.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!